SYT-510 is an endocannabinoid reuptake inhibitor, or "selective endocannabinoid reuptake inhibitor" ("SERI"), which is under development for the treatment of anxiety disorders, mood disorders, and traumatic stress disorders. It is said to mildly and selectively increase levels of endocannabinoids like anandamide via inhibition of a newly identified biological target. As of January 2024, the drug is in the preclinical stage of development or is entering phase 1 clinical trials for the preceding indications. It is under development by a pharmaceutical company called Synendos Therapeutics.